Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company has heard back from the U.S. Food and Drug Administration at their Investigational New Drug meeting for NP-120 or Ifenprodil for the treatment of small-cell lung cancer.
Moreau telling Proactive that the feedback they received has led them to the decision to not plan any additional pre-clinical research and will immediately move to file an application to begin a Phase 1 study as soon as possible.